Home
Torin 2

Torin 2

Catalog No.

B1640

MTOR inhibitor,highly potent and selective

Skip to the beginning of the images gallery

Grouped product items
Size	Price	Stock
10mM (in 1mL DMSO)	$121.00	In stock
10mg	$116.00	In stock
50mg	$345.00	In stock
200mg	$931.00	In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background
Product Citation
Chemical Properties
Protocol
Biological Activity
Quality Control

Background

Torin2 is a potent, selective and orally available inhibitor of mTOR with EC50 value of 0.25nM [1].

Torin2 is a highly potent and selective mTOR inhibitor. It is easier to produce than its lead compound Torin1 and displays improved pharmacokinetic properties. Torin2 is predicted to engage in hydrogen bonds with V2240 and Y2225 of a homology model of mTOR. It also form two hydrogen bonds between the aniline amino group of it with D2195 and D2357, making it more potent than Torin1. Besides that, Torin2 shows excellent overall selectivity and has strong binding to mTOR, CSNK1E, several PI3Ks, CSF1R and MKNK2. Torin2 exerts 800-fold cellular selectivity relative to inhibition of PI3K and other protein kinases. Moreover, Torin2 shows good bioavailability and exposure in vivo [1].

References:
[1] Liu Q, Wang J, Kang S A, et al. Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl) phenyl) benzo [h][1, 6] naphthyridin-2 (1 H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer. Journal of medicinal chemistry, 2011, 54(5): 1473-1480.

Product Citation

Chemical Properties

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	432.41
Cas No.	1223001-51-1
Formula	C24H15F3N4O
Solubility	≥21.6 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
Chemical Name	9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one
SDF	Download SDF
Canonical SMILES	C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Kinase experiment [1]:
mTOR and PI3K Cellular Assays	Cellular IC50 values for mTOR are determined using p53-/- MEFs. Cells are treated with vehicle or increasing concentrations of Torin 2 for 1 h and then lyse. Phosphorylation of S6K1 Thr-389 is monitored by immunoblotting using a phospho-specific antibody. Meanwhile, cellular IC50 values for PI3Ka are determined based on phosphorylation of Akt Thr-308 in p53-/-/mLST8-/- MEFs or human PC3 cells expressing the S473D mutant of Akt1.
Cell experiment:
Cell lines	Human medullary thyroid carcinoma (MTC) cell lines (MZ-CRC-1 and TT cells)
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reacting condition	50, 100 nM; 3 days or 5 days;
Applications	Torin2 exhibited a 0.25 nM EC50 for inhibiting cellular mTOR activity while maintaining 800-fold cellular selectivity over inhibition of PI3K and most other protein kinases [1]. Moreover, Torin2 induced a significant reduction in viability and migration of both MZ-CRC-1 and TT cells [2].
Animal experiment:
Animal models	Male C57BL/6 mice model; female nude mice model
Dosage form	20 mg/kg; oral gavage; for 6 hours; or 2 mg/kg, intraperitoneal injection, twice weekly for 5 weeks
Applications	Torin2 (20 mg/kg) showed good bioavailability and exposure and maintained strong inhibition of mTOR activity in lung and liver to at least 6 hours [1]. Moreover, the combination of Torin2 and cisplatin synergistically inhibited tumor growth in nude mice [3].
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: 1. Liu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Hur, W., Ahmed, T., Sabatini, D. M. and Gray, N. S. (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2( 1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem. 54, 1473-1480 2. Tamburrino, A., Molinolo, A. A., Salerno, P., Chernock, R. D., Raffeld, M., Xi, L., Gutkind, J. S., Moley, J. F., Wells, S. A., Jr. and Santoro, M. (2012) Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res. 18, 3532-3540 3. Hussain, A. R., Al-Romaizan, M., Ahmed, M., Thangavel, S., Al-Dayel, F., Beg, S., Uddin, S., Siraj, A. K. and Al-Kuraya, K. S. (2015) Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer. Mol Med. 21, 466-478

Biological Activity

Description	Torin 2 is a potent and selective inhibitor of mTOR with an IC50 value of 0.25 nM.
Targets	mTOR	ATM	ATR	DNA-PK
IC50	0.25 nM	28 nM(EC50)	35 nM(EC50)	118 nM(EC50)

Quality Control

Quality Control & MSDS

View current batch:

Purity = 99.91%

Chemical structure

Torin 2

mRNA synthesis

Tyramide Signal Amplification (TSA)

Phos Binding Reagent Acrylamide

Cell Counting Kit-8 (CCK-8)

Inhibitor Cocktails

Background

Product Citation

Chemical Properties

Protocol

Biological Activity

Quality Control

Quality Control & MSDS

Chemical structure

Related Biological Data

Related Biological Data

Related Biological Data

Related Biological Data

Product Catalog

Order Info

Customer Service

Contact Us

Newsletter

Follow Us